Paul Griffin

7.0k total citations · 1 hit paper
88 papers, 2.9k citations indexed

About

Paul Griffin is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Infectious Diseases. According to data from OpenAlex, Paul Griffin has authored 88 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Public Health, Environmental and Occupational Health, 16 papers in Epidemiology and 15 papers in Infectious Diseases. Recurrent topics in Paul Griffin's work include Malaria Research and Control (16 papers), Computational Drug Discovery Methods (8 papers) and Mosquito-borne diseases and control (6 papers). Paul Griffin is often cited by papers focused on Malaria Research and Control (16 papers), Computational Drug Discovery Methods (8 papers) and Mosquito-borne diseases and control (6 papers). Paul Griffin collaborates with scholars based in Australia, United States and Switzerland. Paul Griffin's co-authors include James McCarthy, Manos Perros, Patrick Dorr, Carolyn Napier, Malcolm Macartney, Mike Westby, C. Alexopoulos, Blanda Stammen, David A. Price and Rob Webster and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Paul Griffin

86 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity

2005 909 citations Patrick Dorr, Mike Westby et al. profile →

Peers

Countries citing papers authored by Paul Griffin

Since Specialization

Citations

This map shows the geographic impact of Paul Griffin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Griffin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Griffin more than expected).

Fields of papers citing papers by Paul Griffin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Griffin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Griffin. The network helps show where Paul Griffin may publish in the future.

Co-authorship network of co-authors of Paul Griffin

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Griffin. A scholar is included among the top collaborators of Paul Griffin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Griffin. Paul Griffin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	QuLTSF: Long-Term Time Series Forecasting with Quantum Machine Learning 2025 ·(unknown), Paul Griffin, Ariel Neufeld, Jayne Thompson, Mile Gu	1
2	Metagenomics: a new frontier for routine pathology testing of gastrointestinal pathogens 2025 ·Gut Pathogens ·Nicola Angel, Mitchell J. Sullivan, Areej Alsheikh-Hussain, Liang Fang, (unknown), Alena L. Pribyl, (unknown), Gene W. Tyson, Philip Hugenholtz, Donovan H. Parks, Paul Griffin, David Wood	2
3	VIOLET: Visual Analytics for Explainable Quantum Neural Networks 2024 ·IEEE Transactions on Visualization and Computer Graphics ·(unknown), (unknown), Qiang Guan, Paul Griffin, (unknown), (unknown), Yong Wang	3
4	Syphilis in pregnancy: a qualitative investigation of healthcare provider perspectives on barriers to syphilis screening during pregnancy in south-east Queensland 2023 ·Sexual Health ·(unknown), James A. Fowler, Clare Nourse, (unknown), Sumudu Britton, (unknown), Paul Griffin, (unknown), (unknown), Judith A. Dean	8
5	Barriers to optimal management of syphilis in pregnancy and congenital syphilis in south-east Queensland: a qualitative investigation 2023 ·Sexual Health ·James A. Fowler, (unknown), Clare Nourse, (unknown), Sumudu Britton, (unknown), Paul Griffin, (unknown), (unknown), Judith A. Dean	3
6	A first-in-human study of BLZ-100 (tozuleristide) demonstrates tolerability and safety in skin cancer patients 2021 ·Contemporary Clinical Trials Communications ·Miko Yamada, Dennis M. Miller, Melinda Lowe, Casey Rowe, (unknown), H. Peter Soyer, Kelly Byrnes-Blake, Julia Parrish-Novak, Laura Ishak, James M. Olson, Gordon Brandt, Paul Griffin, Lynda Spelman, Tarl W. Prow	25
7	Pentosan polysulfate sodium for Ross River virus-induced arthralgia: a phase 2a, randomized, double-blind, placebo-controlled study 2021 ·BMC Musculoskeletal Disorders ·Ravi Krishnan, (unknown), Penny A. Rudd, Donna Skerrett, James Pollard, (unknown), (unknown), Jennifer Ng, Peter Georgius, (unknown), Paul Griffin	7
8	A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults 2020 ·Human Vaccines & Immunotherapeutics ·Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha Railkar, (unknown), Wen Liu, Jeffrey R. Sachs, (unknown), Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther	111
9	Pharmacokinetics and Pharmacodynamics of a Proposed Pegfilgrastim Biosimilar MSB11455 Versus the Reference Pegfilgrastim Neulasta in Healthy Subjects: A Randomized, Double-blind Trial 2020 ·Clinical Therapeutics ·Jason D. Lickliter, (unknown), Emmanuelle Vincent, Armin Schueler, (unknown), Corinne Seng Yue, Michael Ståhl, Martin Ullmann, (unknown), Paul Griffin	4
10	Altered airway ciliary orientation in patients with X-linked retinitis pigmentosa 2019 ·Thorax ·(unknown), Paul Griffin, Paul Martinello, Robb U. de Iongh, Jonathan B. Ruddle, Philip Robinson	4
11	Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study 2017 ·The Lancet Infectious Diseases ·James McCarthy, Julie Lotharius, Thomas Rückle, Stephan Chalon, Margaret A. Phillips, Suzanne Elliott, Silvana Sekuloski, Paul Griffin, Caroline L. Ng, David A. Fidock, Louise Marquart, Noelle S. Williams, Nathalie Gobeau, Lidiya Bebrevska, Maria Rosario, Kennan C. Marsh, Jörg J. Möhrle	82
12	Safety, acceptability and tolerability of uncoated and excipient-coated high density silicon micro-projection array patches in human subjects 2017 ·Vaccine ·Paul Griffin, Suzanne Elliott, Kenia G. Krauer, Cristyn Davies, S. Rachel Skinner, Christopher D. Anderson, Angus H. Forster	39
13	MALDI-TOF MS meets WGS in a VRE outbreak investigation 2016 ·European Journal of Clinical Microbiology & Infectious Diseases ·Sanmarié Schlebusch, Gareth Price, (unknown), (unknown), Liam D. H. Elbourne, Paul Griffin, Deon J. Venter, Slade O. Jensen, Sebastiaan J. van Hal	16
14	Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers 2016 ·Journal of Antimicrobial Chemotherapy ·James McCarthy, Mark Baker, Peter O’Rourke, Louise Marquart, Paul Griffin, Rob Hooft van Huijsduijnen, Jörg J. Möhrle	51
15	A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study 2016 ·Malaria Journal ·James McCarthy, Thomas Rückle, (unknown), Cathy Cantalloube, (unknown), Mark Baker, Peter O’Rourke, Paul Griffin, Louise Marquart, Rob Hooft van Huijsduijnen, Jörg J. Möhrle	81
16	Plasmodium vivax Controlled Human Malaria Infection – Progress and Prospects 2016 ·Trends in Parasitology ·Ruth Payne, Paul Griffin, James McCarthy, Simon J. Draper	39
17	Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission 2016 ·PLoS neglected tropical diseases ·Paul Griffin, Cielo Pasay, Suzanne Elliott, Silvana Sekuloski, Maggy T. Sikulu-Lord, Leon E. Hugo, David S. Khoury, Deborah Cromer, Miles P. Davenport, Jetsumon Sattabongkot, Karen Ivinson, Christian F. Ockenhouse, James McCarthy	36
18	Fasting increases serum bilirubin levels in clinically normal, healthy males but not females: a retrospective study from phase I clinical trial participants 2014 ·Journal of Clinical Pathology ·Paul Griffin, Suzanne Elliott, Kerry J. Manton	9
19	Chapter 2 CCR5 Pharmacology Methodologies and Associated Applications 2009 ·Methods in enzymology on CD-ROM/Methods in enzymology ·(unknown), Sarah Able, Paul Griffin, (unknown), Ian James, Malcolm Macartney, (unknown), James E. Mills, Carolyn Napier, Iva Navrátilová, Manos Perros, (unknown), (unknown), Elna van der Ryst, Mike Westby, Patrick Dorr	13
20	LARGE STRAIN MEASUREMENTS IN GEOGRID REINFORCEMENT 1994 ·Transportation Research Record Journal of the Transportation Research Board ·Khalid Farrag, (unknown), Paul Griffin	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact